Skip to Content
You are currently on the new version of our website. Access the old version .
CancersCancers
  • Article
  • Open Access

30 May 2025

19 Pages

Radiomic Features Prognosticate Treatment Response in CAR-T Cell Therapy

,
,
,
and
1
Department of Machine Learning, H Lee Moffitt Cancer Center, Tampa, FL 33612, USA
2
Department of Diagnostic & Interventional Radiology, H Lee Moffitt Cancer Center, Tampa, FL 33612, USA
3
Department of Biostatistics & Bioinformatics, H Lee Moffitt Cancer Center, Tampa, FL 33612, USA
4
Department of Blood and Marrow Transplant, H Lee Moffitt Cancer Center, Tampa, FL 33612, USA

Simple Summary

We propose using quantitative imaging metrics (radiomics) derived from the standard of care patient imaging (positron emission tomography/computed tomography, PET/CT) to prognosticate response to advanced axicabtagene ciloleucel (axi-cel) cellular therapy in patients treated for refractory/relapsed Diffused large B-cell lymphoma (DLBCL). We find radiomic (shape, size) characteristics on the imaging scans (PET/CT) of extra nodal lesions are prognostic of survival outcome. These metrics have a high translational ability and can be used for patient selection that can benefit and spare others from these advanced treatments.

Abstract

Background: Diffuse large B-cell lymphomas (DLBCLs) are the most common, aggressive disease form that accounts for 30% of all lymphoma cases. Identifying patients who will respond to these advanced cell-based therapies is an unaddressed challenge. Methods: We propose to develop a radiomics- (quantitative image metric) based signature on the patients’ imaging scans (positron emission tomography/computed tomography, PET/CT) and use these metrics to prognosticate response to axi-cel (axicabtagene ciloleucel), autologous CD19 chimeric antigen receptor (CAR) T-cell (CAR-T) therapy. We curated a cohort of 155 patients with relapsed/refractory (R/R) DLBCL who were treated with axi-cel. Using their baseline image scan (PET/CT), the largest lesions related to nodal/extra-nodal disease were identified and characterized using imaging metrics (radiomics). We used principal component (PC) analysis to reduce the dimensionality of these features across the functional categories (size, shape, and texture). We evaluated the prognostic ability of radiomic-based PC to treatment response (1-year), measured by overall survival (OS) and progression-free survival (PFS). Results: We found that radiomic PC was prognostic of overall survival (Shape-PC, q < 0.013/0.0108, Size-PC, q < 0.003/0.0088), in CT/PET, respectively. In comparison, the metabolic tumor volume (MTV) was prognostic (q < 0.0002/0.0007). The radiomic PCs across the functional categories showed moderate to weak correlation with MTV, Spearman’s ρ of 0.44/0.35/0.27, and 0.45/0.36/0.55 for Size/Shape/Texture-PC1 obtained on PET and CT, respectively. Conclusions: We found radiomic PC based on size and shape metrics that are able to prognosticate treatment response to CAR-T therapy.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.